Quizartinib for Newly Diagnosed <i>FLT3</i> -Internal Tandem Duplication–Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI StudyPau Montesinos, Jorge Labrador, Mar Tormo et al.|Journal of Clinical Oncology|2025Cited by 13
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA GroupTamara Castaño-Bonilla, Pau Montesinos, Eva Barragán et al.|Disease Markers|2022Cited by 2
Conventional PCR Versus Next Generation Sequencing for Diagnosis of FLT3, IDH and NPM1 Mutations in Acute Myeloid Leukemia: Results of the PETHEMA PCR-LMA StudyBlanca Boluda, Pau Montesinos, Rebeca Rodríguez‐Veiga et al.|Cancers|2025Cited by 2
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registryAna Alfonso Piérola, David Martínez‐Cuadrón, Rebeca Rodríguez‐Veiga et al.|Leukemia|2025Cited by 1